AVDL — Avadel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.11bn
- $2.06bn
- $169.12m
Brief: Avadel Pharmaceuticals Says Delaware District Court Denied Request By Jazz Pharma On Permanent Injunction To Enjoin Co's Unit From Selling LUMRYZ
Brief: Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ
Avadel Pharmaceuticals PLC reports results for the quarter ended in June - Earnings Summary
Avadel Pharmaceuticals PLC expected to post a loss of 16 cents a share - Earnings Preview
Brief: Avadel Pharmaceuticals PLC Files For Common Stock Offering Of Up To $100 Million - SEC Filing
Avadel Pharmaceuticals PLC reports results for the quarter ended in January - Earnings Summary
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
Avadel Pharma rises on strong demand for sleep disorder drug
Brief: Avadel Pharmaceuticals Q4 EPS USD -0.32
Avadel Pharmaceuticals PLC reports results for the quarter ended in December - Earnings Summary
Avadel Pharmaceuticals PLC expected to post a loss of 29 cents a share - Earnings Preview
Avadel climbs on upbeat Q4 2023 prelim revenue
Brief: Avadel Pharmaceuticals Announces Strong Lumryz Launch Performance
Brief: Avadel Pharmaceuticals Provides Corporate Update And Reports Third Quarter 2023 Financial Results
Brief: Avadel Pharmaceuticals Q3 EPS USD -0.41
Brief: Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ (sodium oxybate) For Extended-Release Oral Suspension
Avadel Pharmaceuticals PLC reports results for the quarter ended in June - Earnings Summary